Clinical posts from members and guests of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM) from various international medical and scientific conferences on HIV, AIDS, viral hepatitis, and sexual health.
Still very early data presented on maturation inhibitor BMS-955176
Data from the BMS-955176 Phase IIa proof of concept study was presented.
Short 10 day monotherapy were conducted for HIV-1 subtype B and C in treatment naive or experienced subjects to demonstrate virologic suppression. 1.64 log was achieved at doses above 40mg for B and 1.35 log for C.
The study also concluded comparable virologic control over 28 days with standard of care TDF+FTC+ATV/R with a 2.23 log fall in viral load at Day 28.
Still too early to tell I think.
Tagged in: EACS2015
Trackback URL for this blog entry.